First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-10-01 21:56:22Open Document File Size: 100,33 KBShare Result on FacebookCityTrial / /CompanyUSA Agency for Healthcare Research / Norgine Pty Ltd / New England Journal / Philips / PBAC / /CountryAustralia / /CurrencyUSD / /EventProduct Recall / FDA Phase / Product Issues / /IndustryTermrifaximin / study protocol / treatment of irritable bowel syndrome / comparator / proposed managed entry scheme study protocol / prospective trial protocol / /MedicalConditionA. et al Chronic / reversible neuropsychiatric disorder / disease / coma / cirrhosis / hepatic encephalopathy / hepatic encephalopathy patients / fulminant hepatic failure / portal hypertension / overt hepatic encephalopathy / chronic liver failure / delirium / asterixis / End-Stage Liver Disease / irritable bowel syndrome / hepatic insufficiency / /OrganizationUSA Agency for Healthcare Research and Quality / Antimicrobial Resistance Subcommittee / /Positiondriver / Publication title author / /ProductRifaximin / previous acceptance / Xifaxan / lactulose / previous concern / PBAC / RFHE3001 / sponsor / /ProvinceOrStateConnecticut / /PublishedMediumNew England Journal of Medicine / /RegionNew England / /Technologystudy protocol / detailed prospective trial protocol / proposed managed entry scheme study protocol / /URLhttp /SocialTag |